Government Tightens Rules on Stem Cell Therapy Use

The Union Ministry of Health and Family Welfare rolled out a fresh advisory on Thursday, reminding every state and Union territory that stem‑cell therapy may be offered as routine clinical care only for conditions officially approved by the centre.

Why the sudden push? It stems from a Supreme Court verdict dated 30 January 2026 in the case of Yash Charitable Trust & Ors. v. Union of India & Ors. The court warned that any deviation from the prescribed framework could invite serious legal consequences.

In plain language, the ministry wants to see stem‑cell procedures confined to the list of disease indications that it has already vetted. Anything outside that list – be it a promise of miracle cures or a loosely‑promoted “anti‑aging” package – would be deemed a breach of the law.

When it comes to Autism Spectrum Disorder (ASD), the advisory is crystal clear: stem‑cell interventions are permitted only within the bounds of duly authorised clinical trials. This aligns with the National Guidelines for Stem Cell Research (2017), a joint effort of ICMR and the Department of Biotechnology, and any stray usage would be considered illegal.

The Ministry has asked state and district health authorities, as well as private and public hospitals, to circulate the Supreme Court’s directions far and wide. Those who ignore the rulebook could face penalties under Regulation 7.22 of the IMC Regulations 2002, or even see their licences cancelled under Sections 32 and 40 of the Clinical Establishments (Registration and Regulation) Act 2010.

Reinforcing the stance, the National Medical Commission (NMC) released its own advisory on 5 September, echoing that stem‑cell therapy must stay within the approved indications. The NMC warned that any unauthorised prescription, advertisement or administration would amount to professional misconduct, urging state medical councils to investigate complaints and, where warranted, impose sanctions after due process.

In short, the message is unmistakable: stem‑cell therapy in India is a regulated medical service, not a commercial free‑for‑all. The government is tightening the net to protect patients from unproven claims while still allowing legitimate research to move forward under strict oversight.